University of Idaho, Utah State University team first to clone equine

May 29, 2003

MOSCOW, Idaho -- A University of Idaho-Utah State University research team is the first worldwide to clone a member of the horse family, a mule, according to an article to be published in the journal Science.

The research team includes Gordon Woods, UI professor of animal and veterinary science, Kenneth L. White, Utah State University professor of animal science, and Dirk Vanderwall, UI assistant professor of animal and veterinary science.

The baby mule, Idaho Gem, was born May 4. It is the first clone of a hybrid animal. A mule results from a cross between a female horse, a mare, and a male donkey, a jack. As hybrids, mules are sterile, except in extremely rare cases.

Veterinary examinations of the foal and its surrogate mother showed them to be in good health, Woods said. The foal romped with its surrogate mother during a news conference on the UI campus this morning to announce its birth.

The foal's DNA comes from a fetal cell culture first established in 1998 at the University of Idaho.

As scientifically and commercially significant as their accomplishment is for the horse industry, Woods said he is most excited because the project provides a new animal model, the horse, to advance understanding of human cancer.

Woods believes the breakthrough understanding of cellular biology necessary for horse cloning to proceed may offer new insights into cancer development in humans.

Woods, UI professor of animal and veterinary science, began working on the cloning project in 1998. As director of the Northwest Equine Reproduction Laboratory on the UI Moscow campus, he has spent much of his career studying horse-breeding issues.

Horses present a large challenge to those who would use advanced technology to assist them. Only two "test-tube" horse foals, babies conceived in a test tube, have resulted from in vitro fertilization experiments worldwide.

The mule clone born in May is the full sibling of a champion racing mule owned by Idaho businessman, UI benefactor and mule enthusiast Don Jacklin of Post Falls.

For three years, from 1998 to 2000, the team worked without apparent success. After transferring the nuclei from the mule cells into 134 horse eggs and implanting them into mares, two apparently "false pregnancies" resulted, but both failed to proceed past four weeks.

In 2001, the team began to focus on the calcium levels in the fluid surrounding the eggs during the cloning procedure. The change led to the first fetal heart beat, signifying the team had crossed a significant hurdle in the experiment. That year, researchers transferred 84 eggs, establishing five apparent pregnancies.

"The results were impressive and immediate," Woods said. The first change led to a significant advance in the development of cloned embryos.

In 2002, Woods, White and Vanderwall continued to adjust the calcium levels in the fluid surrounding the egg during the cloning procedure. That change dramatically increased the team's success.

The team established 14 pregnancies using mule DNA in 113 attempts. Eight of the pregnancies continued to at least the 40-day stage when heartbeats were detected.

To test whether mule DNA could be limiting success, the team also made 61 attempts to use horse DNA. The test resulted in seven apparent pregnancies, two of which developed heartbeats. Neither of the horse clone pregnancies developed past the critical 60-day threshold, however.

The UI-Utah State team is the first to succeed among several teams worldwide attempting to clone a member of the horse family. The 2002 preliminary testing showed the method developed by the researchers to successfully clone a mule should work equally as well with a horse, Woods said.

"It basically came down to a matter of numbers, and we wanted to focus most of our attention on cloning a mule, which was our original objective," Vanderwall said.

White is widely recognized as an expert on cattle cloning and brought cloning expertise to the team. Vanderwall, who like Woods, earned doctor of veterinary medicine and Ph.D. degrees, brought extensive clinical expertise to the team.

Woods had taken an interest in basic horse physiology after becoming intrigued by the observation that stallions, male horses, do not develop prostate cancer.

The horse's basic metabolism is "slow" compared to humans and many other mammals, Woods said. He speculated that difference in cellular activity might play a role in both cancer development and reproduction.

He formed an outside company, Cancer2, to investigate that observation with the backing of private investors. The studies showed a fundamental difference between men and stallions in the calcium concentrations within the cells and surrounding fluid. Woods said the team will explore other lines of scientific inquiry opened by this year's success.
-end-
EDITORS: The University of Idaho will provide a satellite feed with highlights from Thursday morning's news conference as well as file video between 12:30 and 12:45 p.m., PDT, at Ku band, AMC 3, Transponder 15, Polarity: Horizontal 87 degrees W, Downlink frequ. 12000, Audio 6.2/6.8. In addition, reporters from the United States can join the news conference by telephone by calling 800-553-0318; reporters from outside the U.S. can join by calling 612-288-0340. News releases, scientist biographies, photos, video and sound bites are available a www.uidaho.edu/clones. CONTACTS: Kathy Barnard or Bill Loftus, University Communications, 208-885-6291, kbarnard@uidaho.edu or bloftus@uidaho.edu

University of Idaho

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.